NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND ASSOCIATED FACTORS IN PATIENTS WITH TYPE 2 MELLITUS DIABETES

Thị Mỹ Hạnh Hoàng, Quang Bảy Nguyễn

Main Article Content

Abstract

Aim: to describe the clinical, laboratory characteristics and associated factors with non-alcoholic fatty liver disease (NAFLD) in patients with diabetes mellitus type 2 (DM2). Subject and methods: a cross-sectional study among 70 patients with DM2 aged 18-70 in Endoscrinoloy Department & Endocrine consulting room – Bach Mai Hospital and satified the criteria of American Association for Liver Diseases (AASLD) 2018 about NAFLD. All participants underwent abdominal ultrasould and Fibroscan to measure liver stiffness (LSM) and liver steatosis (CAP). Results: 52,9% patients were female, the mean age was 51.3 ± 12.7. 71.4% patients were overweight/obese. In Fibroscan, 82.9% patients had liver steatosis, the prevalence of grade 1, 2, 3 were 24.3%, 11.4%, and 47.1%, respectively. BMI, waist-hip ratio, ALT and LSM were signigicantly higher in patients with liver steatosis grade 3 than grade 1-2 and normal ones. BMI, HbA1c, HDL-C and LSM were associated with CAP. Conclusion: High prevalance of patients with DM2 had liver steatotis in Fibroscan. CAP, an index for liver steatosis, was associated with BMI, HbA1c, HDL-C and LSM.

Article Details

References

1. Chalasani, N., et al., The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology, 2018. 67(1): p. 328-357.
2. Younossi, Z.M., et al., Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology, 2016. 64(1): p. 73-84.
3. Dyson, J.K., Q.M. Anstee, and S. McPherson, Non-alcoholic fatty liver disease: a practical approach to diagnosis and staging. Frontline Gastroenterol, 2014. 5(3): p. 211-218.
4. Lim, J.U., et al., Comparison of World Health Organization and Asia-Pacific body mass index classifications in COPD patients. Int J Chron Obstruct Pulmon Dis, 2017. 12: p. 2465-2475.
5. Pozzan, R., et al., Risk factors associated with nonalcoholic fatty liver disease evaluated by elastography in patients with type 2 diabetes. Arch Endocrinol Metab, 2022. 66(4): p. 452-458.
6. Tuong, T.T.K., et al., Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes: Evaluation of Hepatic Fibrosis and Steatosis Using Fibroscan. Diagnostics (Basel), 2020. 10(3).
7. Lomonaco, R., et al., Advanced Liver Fibrosis Is Common in Patients With Type 2 Diabetes Followed in the Outpatient Setting: The Need for Systematic Screening. Diabetes Care, 2021. 44(2): p. 399-406.
8. Wang, Y., et al., Controlled attenuation parameter for assessment of hepatic steatosis grades: a diagnostic meta-analysis. Int J Clin Exp Med, 2015. 8(10): p. 17654-63.
9. Kwok, R., et al., Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut, 2016. 65(8): p. 1359-68.
10. Lai, L.L., et al., Screening for non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus using transient elastography. J Gastroenterol Hepatol, 2019. 34(8): p. 1396-1403.